265 related articles for article (PubMed ID: 26013187)
1. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
2. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the therapeutic effects of febuxostat combined with a low-purine diet and allopurinol combined with a low-purine diet on the improvement of gout patients.
Chen X; Ye T; Dai Y; Li P; Zhao X; Yu Y; Wang X; Jiao X; Shen N
Int J Rheum Dis; 2024 May; 27(5):e15165. PubMed ID: 38769820
[TBL] [Abstract][Full Text] [Related]
4. "Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial.
Yu XN; Wu HY; Deng YP; Zhuang GT; Tan BH; Huang YZ; Tang SY; Tu X; Jordan JB; Zhong S
Trials; 2018 Oct; 19(1):551. PubMed ID: 30314508
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
Wu F; Chen L; Du Y
Clin Rheumatol; 2024 May; 43(5):1745-1754. PubMed ID: 38492092
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
[TBL] [Abstract][Full Text] [Related]
7. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
[TBL] [Abstract][Full Text] [Related]
8. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
[TBL] [Abstract][Full Text] [Related]
9. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia: A real-world multicenter retrospective study.
Si X; Huang L; Ding Q; Zhang W; Zhao R; Ai C; An Z; Liu G; Zhang C; Zhong X; Feng Y
Medicine (Baltimore); 2024 Jan; 103(4):e37081. PubMed ID: 38277524
[TBL] [Abstract][Full Text] [Related]
11. Association between the initial dose urate-lowering drugs and gout flares in adult males with gout.
Li X; Shao Q; Shen J; Ren S; Li L; Lu H; Chen S
Rheumatology (Oxford); 2024 May; 63(6):1599-1606. PubMed ID: 37610331
[TBL] [Abstract][Full Text] [Related]
12. Urate-lowering agents do not have clinically relevant negative effects on sperm quality and reproductive hormones in men with gout: a prospective open-label cohort study.
Li C; Wang Y; Mu R; Zhao J; Yao Z; Zhai J; Jin Y; Liu R; Liu D; Hong K; Jiang H; Zhang Z
Rheumatol Int; 2024 Jul; 44(7):1245-1253. PubMed ID: 38538820
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
Yan CQ; Liang C; Lan ZR; Su C; Xiong SY; Yang YX; Chen JM; Tang SL; Huang JS; Zhang ZH; Luo MJ; Xiao ZH
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11988-12003. PubMed ID: 38164861
[TBL] [Abstract][Full Text] [Related]
14. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.
Huang HH; Chen YY; Fang YW; Liou HH; Wang JT; Tsai MH
Med Sci Monit; 2024 Jun; 30():e944314. PubMed ID: 38865287
[TBL] [Abstract][Full Text] [Related]
15. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
Givertz MM; Anstrom KJ; Redfield MM; Deswal A; Haddad H; Butler J; Tang WH; Dunlap ME; LeWinter MM; Mann DL; Felker GM; O'Connor CM; Goldsmith SR; Ofili EO; Saltzberg MT; Margulies KB; Cappola TP; Konstam MA; Semigran MJ; McNulty SE; Lee KL; Shah MR; Hernandez AF;
Circulation; 2015 May; 131(20):1763-71. PubMed ID: 25986447
[TBL] [Abstract][Full Text] [Related]
16. Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study.
Takeshita M; Tanaka A; Yoshida H; Nakamura I; Shibata Y; Hata S; Kushiyama A; Okutsu M; Ishizu T; Node K
J Atheroscler Thromb; 2024 Jun; 31(6):864-875. PubMed ID: 38220209
[TBL] [Abstract][Full Text] [Related]
17. What Is Allopurinol Failure and What Should We Do About It?
Stamp LK; Dalbeth N
J Rheumatol; 2024 Jun; 51(6):556-562. PubMed ID: 38490676
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
[TBL] [Abstract][Full Text] [Related]
19. Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial.
Singh JA
BMC Med; 2012 Feb; 10():15. PubMed ID: 22316088
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat in the management of hyperuricemia and chronic gout: a review.
Hu M; Tomlinson B
Ther Clin Risk Manag; 2008 Dec; 4(6):1209-20. PubMed ID: 19337428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
